Investing in Exponential Growth Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Investing in Exponential Growth

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Paul H. Christiansen	9/6/2018 7:42:13 AM
	of 1084

CRISPR Technology Still Holds Big Promise The gene-editing technology called CRISPR has worked such wonders in laboratories that Wall Street values the technique’s three pioneers at a collective $5 billion, even though nobody’s tested the stuff in people yet. A shudder recently ran through the stocks— Crispr Therapeutics (ticker: CRSP), Editas Medicine (EDIT), and Intellia Therapeutics (NTLA)—after a few scientific studies raised concerns that gene-editing therapy might have serious side effects. But the CRISPR crew said the studies were false alarms and are proceeding with plans for clinical trials of the technique, which can home in on a faulty stretch of a cell’s genetic code and rewrite it to potentially cure diseases like hemophilia or cystic fibrosis. If you don’t need to put CRISPR in humans, then side effects are not an issue. Unlike CRISPR medicines, diagnostic tests can use the technology outside of a patient. And CRISPR shows exciting promise for making fast, cheap tests that could screen a sample of blood or saliva for signs of cancer or infectious diseases like Zika. *Read More $ Barron’s*

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next